Envigo at SOT 2018

Envigo is proud to be attending the Society of Toxicology 2018 Annual Meeting. Learn more

Explore our Envigo blog

Bringing you the latest thinking and insights to help you reach your critical milestones. Visit our blog

Research models

Use our advanced search tool below to find the exact model you need.


Quick Links

Health and genetic monitoring reports
Cell line references

Envigo Announces Termination of Transaction Agreement with Avista Healthcare Public Acquisition Corp.

The Transaction Agreement with Avista Healthcare Public Acquisition Corp. ("AHPAC") has been terminated by mutual agreement, due to unfavorable market conditions. Read More

Lynn Lewis appointed Senior Vice President Global Sales

Lynn Lewis brings extensive knowledge in both science and business to the company through her successful career in pharmaceuticals and leadership roles within sales and operations in the contract research organization (CRO) industry. Read More

Envigo Allocates $300 Million Term Loan B Facility

Proceeds from the term loan will be used to refinance the company’s existing debt in connection with the closing of its previously-announced definitive merger agreement with Avista Healthcare Public Acquisition Corp. (NASDAQ: AHPA) (“AHPAC”), a special purpose acquisition company. Read More

See All Latest News
Envigo oncology brochure (USA | EU)

At Envigo, we understand that our customers conduct research and develop products that have the potential to offer significant improvements to global health and the environment. We also realize achieving that potential has grown more challenging. That is why we remain focused on your goals, needs and expectations, ensuring you have a trusted partner to advance your life-changing research and products.

Developments in LifeSciences Vol. 15, No. 1

In this issue:
• 20 critical questions for ensuring inhaled crop protection and chemical registration
• The CRO landscape — An evolving safety testing market
• Substance identity: The critical component of both lead and co-registrant dossiers
• The extended one-generation reproductive toxicity study (EOGRTS), OECD test guideline 443

Webinar on-demand
Key considerations in the safety evaluation of drugs targeting immune checkpoints

Presented by Lee Coney (Chief Scientific Officer - Biologics) and Mandy Horn (Supervisor - Veterinary Science, Research and Support). You will learn what is cancer immunotherapy; what are the potential challenges in the safety assessment of antibodies targeting immune system checkpoints?; Things to consider when designing and running your nonclinical safety programmes for immune checkpoint targets; and more.

See all insights